ArticleFrontiers in clinical diabetes and healthcare2025
Real-world clinical and budget impact of semaglutide in type 2 diabetes mellitus in tertiary hospital in Saudi Arabia.
Article in Frontiers in clinical diabetes and healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this research is to evaluate the clinical and economic benefits of semaglutide in patients with type 2 diabetes mellitus (T2DM) in real-world setting in tertiary hospital in Saudi Arabia. Methods: In this single-center retrospective chart review study, patients were included if they were adults and diagnosed with T2DM for at least one year between January 2017 and December 2023. Patients were excluded if they had previously received glucagon-like peptide-1 receptor agonist (GLP-1RA). The primary outcomes were HbA1c level and Body Mass Index (BMI). Secondary outcomes were the number of outpatient visits, emergency room visits, hospitalization days and total per patient costs. Results: The study included a total of 186 patients who were initiated on semaglutide. After 12 months on semaglutide, patients' median HbA1c was reduced from 8.9% [8.4 - 9.9] to 7.8% [7.2 - 8.4] ( Conclusion: Semaglutide was associated with significant improvement in glycemic and weight-loss control in adults with T2DM, but this significant change was associated with higher overall cost mainly driven by medication cost.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.